(2,5-Dioxopyrrolidin-1-yl)di(prop-2-en-1-yl)sulfanium chloride | 59321-39-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: (2,5-Dioxopyrrolidin-1-yl)di(prop-2-en-1-yl)sulfanium chloride
• 英文别名: (2,5-dioxopyrrolidin-1-yl)-bis(prop-2-enyl)sulfanium;chloride
• CAS: 59321-39-0
• 化学式: C10H14ClNO2S
• 分子量: 247.74
• InChiKey: XFNYJFNCDDQOSV-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  -1.96
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  38.4
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• Substituted indoles as alpha-1 agonists
  申请人：——

  公开号：US20030220319A1

  公开（公告）日：2003-11-27

  This invention relates to compounds which are alpha-1 receptor agonists, preferably alpha-1A/L receptor agonists, and which are represented by Formula I: 1 wherein X is —S(O) n — or —C(O)—, A is C 1-6 alkyl, aryl, heteroaryl, hydroxyalkyl, or —(CH 2 ) p —NR a R b , and the other substituents are as defined in the specification; or individual isomers, racemic or non-racemic mixtures of isomers, or pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds, methods for their use as therapeutic agents, and methods of preparation thereof.

  这项发明涉及α-1受体激动剂，优选为α-1A/L受体激动剂，其化学式如下：其中X为—S(O)n—或—C(O)—，A为C1-6烷基，芳基，杂环芳基，羟基烷基，或—(CH2)p—NRaRb，其他取代基如规范中所定义；或其各个异构体，消旋体或非消旋体混合物，或其药用盐或溶剂化合物。该发明还涉及含有这类化合物的药物组合物，以及它们作为治疗剂的使用方法和制备方法。
• SUBSTITUTED INDOLES AS ALPHA-1 AGONISTS
  申请人：F. Hoffman-la Roche AG

  公开号：EP1501826B1

  公开（公告）日：2006-09-27
• US6852726B2
  申请人：——

  公开号：US6852726B2

  公开（公告）日：2005-02-08
• [EN] SUBSTITUTED INDOLES AS ALPHA-1 AGONISTS<br/>[FR] INDOLES SUBSTITUES EN TANT QU'AGONISTES ALPHA-1
  申请人：HOFFMANN LA ROCHE

  公开号：WO2003064387A2

  公开（公告）日：2003-08-07

  This invention relates to compounds which are alpha-1 receptor agonists, preferably alpha- 1A/L receptor agonists, and which are represented by the general formula I wherein X is -S(O)n- or -C(O)-, A is (CI-6)-alkyl, aryl, heteroaryl, hydroxy(C 1-6)-alkyl, or -(CH2)p-NRaRb, and the other substituents are as defined in the specification; or individual isomers, racemic or non-racemic mixtures of isomers, or pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds, their preparation and their use as therapeutic agents.